LATISSE® | Book A Risk-Free Consultation Today
Before & After Photos
*Disclaimer: Results may vary. The testimonial(s) and information on this website reflect results achieved by these specific patients.
As each case must be independently evaluated and managed by our team of professionals, actual weight loss and results will vary.
Helping To Grow Your Eyelashes
LATISSE® is an FDA-approved treatment to grow eyelashes for people with inadequate or not enough lashes.
Before & After Latisse® Treatment Photos
Disclaimer: Individual Results May Vary.
How Does It Work?
We believe it does so by increasing the growth cycle (anagen) phase of your eyelash hair cycle. Anagen is the growth phase of all hair. We believe that it increases the length of the anagen phase and the number of hairs in this growth phase.
How Is LATISSE® Solution Different From Other Eyelash Growth Products?
Over-the-counter products condition eyelashes. Only LATISSE® has been approved by the FDA as a prescription treatment to grow eyelashes in people with inadequate or not enough eyelashes.
What Does FDA Approved Mean?
The US Food and Drug Administration (FDA) is the federal governmental agency charged with protecting the health and welfare of the US public by regulating prescription products. FDA regulations are extremely stringent, and when a drug is FDA approved, that means its efficacy and safety have been scientifically studied in valid clinical trials. FDA approval also requires the sponsoring pharmaceutical company to record all adverse events reported after the drug is approved. LATISSE® received its FDA approval in December 2008.
How Can Lashes Change Over Time?
Initial data from a group of women diagnosed with eyelash hypotrichosis in the LATISSE® clinical studies suggest that eyelashes may change over time.1,2 These are the trends that were suggested1,2:
- Length decreased with increasing age (based on assessment of 607 women)
- Fullness decreased with increasing age (based on assessment of 468 women)
- Darkness decreased with increasing age (based on assessment of 568 women)
How Do Patients Apply The Product?
Patients should be informed that LATISSE® should be applied every night using only the accompanying sterile applicators. They should start by ensuring their face is clean, all makeup is removed, and their contact lenses are removed (if applicable). Then carefully place one drop of LATISSE® solution on the disposable sterile applicator and brush cautiously along the skin of the upper eyelid margin at the base of the eyelashes. If any LATISSE®solution gets into the eye, it is not expected to cause harm. The eye should not be rinsed. Patients should be informed not to apply to the lower eyelash line. Any excess solution outside the upper eyelid margin should be blotted with a tissue or other absorbent material.
What Are The Most Frequently Reported Adverse Events In The Clinical Study?
The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
How Soon Can Patients Expect Results?
It’s important for patients to remember that LATISSE® solution works gradually. While they may start seeing longer lashes after 4 weeks, they must use LATISSE® every day for 16 weeks for full results. They should not reduce or stop daily application of LATISSE® solution when they first notice results. After 16 weeks, they should talk to their doctor about ongoing use. Individual results may vary.
WARNING: DISTANT SPREAD OF TOXIN EFFECT
LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
Important Safety Information
Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated.
Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
Postmarketing Experience: The following reactions have been identified during postmarketing use of LATISSE® in clinical practice: eye swelling, eyelid edema, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), and vision blurred.